Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

By Rury R. Holman, A. Bethel, R. Mentz, Vivian P. Thompson, Y. Lokhnygina, John B. Buse, J. Chan, Jasmine Choi, S. Gustavson, N. Iqbal and 8 more. New England Journal of Medicine, 2017

1,746 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/5e44edfbbc8407de3dbd07fc18e4b686e8bcbae6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Reinhard W. Holl

Citations in the corpus

• Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers (2019, background): “ing on whether they are able to lower insulin doses during the workout (such as with an insulin pump or reduced preexercise insulin dosage), the time of day exercise is done, and the intensity and duration of the activity (156,171).”
• GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, neutral): “SUSTAIN-6 (subcutaneous semaglutide) [100], 2: PIONEER-6 (oral semaglutide) [101], 3: natide) [97], 6: ELIXA (lixisenatide) [95], 7: EMPA-REG Outcomes (empagliflozin) [120], 8: VERTIS-CV (ertugliflozin, presented at the 80th scientific session of the American Diabet SAVOR-TIMI-53 (saxagliptin) [125]”